KX-826 Received The INCI Designation
Release time：2024-06-05 16:00
Suzhou, June 5, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed KX-826 has recently received the International Nomenclature Cosmetic Ingredient (the “INCI”) review approval from the International Cosmetic Ingredient Nomenclature Committee. The assigned INCI name is Methylpyridinyl Fluoromethoxybenzonitrile Dimethyloxothiooxoimidazolidine.
INCI names are systemic names recognized worldwide for the identification of cosmetic ingredients and are cited by product labeling regulations in many countries. The assignation would facilitate the global launch of the Company's functional cosmetics with KX-826 as the main ingredient.
recommend News
2024-07-01
2024-06-05
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn